A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

NCT06075667 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the safety and effects of the medication tirzepatide, given once a week, in teenagers who have obesity or overweight along with weight-related health issues.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 150 people Planned (estimated).

Who can join Ages 12–17 · all sexes

Timeline Started 2023-10 · est. completion 2029-07

Where 33 sites · Canada, Czechia, Israel, Italy, Poland, United States

What this study is testing ClinicalTrials.gov NCT06075667 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity. The study will last approximately 90 weeks and may include up to 25 visits. Participants who have completed the primary 72-week GPHP study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the opportunity to receive an additional 156 weeks of treatment with tirzepatide as well as continuing the lifestyle intervention.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Percent Change from Baseline in Body Mass Index (BMI)
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06075667 ↗